Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAT-2: Peg-IFN-α2b + bNAbs in HIV
NCT03588715Phase 1Unknown
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peginterferon alfa-2b, Teropavimab and zinlirvimab in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoints: Treatment-related adverse events at 30 weeks, Association between antibody-mediated cell cytotoxicity and NK cell activation and 1 more. Status: unknown.
02
Drugs
peginterferon alfa-2bTeropavimabzinlirvimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03588715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588715.